Step 2/3
Drug-coated balloons (DCB), also referred to as drug-eluting balloons, are used to treat peripheral and coronary artery lesions and restenosis. The balloons carry an antiproliferative drug that is delivered to the wall of arteries when the balloon is expanded. The drug helps prevent neointimal hyperplasia caused by vessel trauma from the balloon angioplasty. Find news and video content on DCBs
March 14, 2023 —MedAlliance has announced enrollment of over 1,000 patients in its ground-breaking SELUTION DeNovo ...
March 14, 2023 
January 27, 2023 — The first US patient has been enrolled at Medstar Washington Hospital Center in the SELUTION4ISR ...
January 27, 2023 
January 12, 2023 — Selution SLR, MedAlliance’s novel sirolimus-eluting balloon, has received conditional FDA ...
January 12, 2023 
January 2, 2023 — The U.S. Food and Drug Administration (FDA) has approved the Stellarex 0.035” OTW Drug-coated ...
January 02, 2023 
November 28, 2022 – BIOTRONIK announced the presentation of one-year results from the investigator-initiatedBIOPACT RCT ...
November 28, 2022 
October 28, 2022 — SELUTION SLR, MedAlliance’s novel sirolimus-eluting balloon, has received FDA Investigational Device ...
October 28, 2022 
October 18, 2022 — Swiss-based medical technology company MedAlliance has announced it has entered into an agreement ...
October 18, 2022 
August 23, 2022 — The first US patient has been enrolled in the FDA SELUTION4BTK (Below-the-Knee) clinical trial ...
August 23, 2022 
July 12, 2022 — Biotronik announced the presentation of two studies on the performance of its drug-coated balloon ...
July 12, 2022 
June 8, 2022 — The first patient has been enrolled in the FDA IDE BTK (Below-the-Knee) SELUTION4BTK clinical trial ...
June 08, 2022